Jim Simons Nls Pharmaceutics Ltd. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Nls Pharmaceutics Ltd. stock. As of the latest transaction made, Renaissance Technologies LLC holds 179,577 shares of NLSP stock, worth $35,915. This represents 0.0% of its overall portfolio holdings.

Number of Shares

179,577

Previous 12,677 1316.56%

Holding current value

$35,915

Previous $7,000 357.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.16 - $0.59 $26,704 - $98,471	166,900 Added 1316.56%	179,577 $32,000
Q4 2023 Feb 13, 2024	SELL	$0.32 - $0.87 $2,695 - $7,328	-8,423 Reduced 39.92%	12,677 $7,000
Q3 2023 Nov 14, 2023	SELL	$0.7 - $1.42 $23,520 - $47,712	-33,600 Reduced 61.43%	21,100 $15,000
Q2 2023 Aug 11, 2023	BUY	$0.92 - $1.56 $20,792 - $35,256	22,600 Added 70.4%	54,700 $60,000
Q1 2023 May 12, 2023	BUY	$1.26 - $1.82 $14,994 - $21,658	11,900 Added 58.91%	32,100 $49,000

Q4 2022 Feb 13, 2023	SELL	$0.48 - $1.29 $2,688 - $7,224	-5,600 Reduced 21.71%	20,200 $26,000
Q3 2022 Nov 14, 2022	BUY	$0.34 - $1.12 $1,972 - $6,496	5,800 Added 29.0%	25,800 $16,000
Q2 2022 Aug 12, 2022	SELL	$0.53 - $1.36 $901 - $2,312	-1,700 Reduced 7.83%	20,000 $12,000
Q1 2022 May 13, 2022	BUY	$0.82 - $1.76 $8,938 - $19,184	10,900 Added 100.93%	21,700 $31,000
Q4 2021 Feb 11, 2022	BUY	$1.11 - $2.56 $11,988 - $27,648	10,800 New	10,800 $12,000
Q3 2021 Nov 12, 2021	SELL	$2.29 - $3.14 $96,173 - $131,870	-41,997 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$2.91 - $4.12 $122,211 - $173,027	41,997 New	41,997 $132,000

Others Institutions Holding NLSP

# of Institutions

Shares Held

8.16M

Call Options Held

Put Options Held

View Full List

About NLS Pharmaceutics Ltd.

Ticker NLSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,349,900
Market Cap $5.87M
Description
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, suc...

More about NLSP

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account